New eye drops aim to soothe stubborn dry eye
NCT ID NCT07234318
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested cyclosporin 0.1% eye drops in 25 adults with moderate to severe dry eye disease that didn't get better with artificial tears. The goal was to see if the drops reduce eye dryness and redness. Participants used the drops alongside their usual tear substitutes for 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclosporin 0.1% eye drops
What this could lead to
If successful, this could provide a new treatment option for people with moderate to severe dry eye disease that hasn't improved with artificial tears.
What could go wrong
This is a small, completed study with only 25 participants. Results may not apply to everyone with dry eye, and cyclosporin eye drops can cause stinging or irritation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of Vienna
Vienna, 1090, Austria